Mirvedol (Memantine Hydrochloride)

Memantine Hydrochloride, the active ingredient in Mirvedol, is an NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults.

GNH USA supplies Mirvedol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirvedol acts on the glutamatergic pathway involved in neurodegeneration, primarily used in Alzheimer’s disease management.

Alzheimer’s disease (moderate to severe): improves cognition and functional abilities. Alzheimer’s disease with behavioral symptoms: may reduce agitation and confusion. Dementia associated with Alzheimer’s disease: supports daily living activities.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial pain. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness or reduced energy. - Confusion: occasional disorientation. - Somnolence: increased sleepiness.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Hallucinations or psychosis: visual or auditory disturbances. - Suicidal thoughts: emergence of depressive ideation. - Cardiac arrhythmias: irregular heart rhythm in susceptible patients.

Before initiating therapy, consider the following precautions: - Renal impairment: assess kidney function and monitor. - Hepatic impairment: use with caution in liver disease. - History of seizures: monitor for increased seizure activity. - Concomitant NMDA‑active agents: avoid additive CNS effects. - Pregnancy and breastfeeding: safety unknown; avoid unless clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with several medicines; review patient medication lists carefully.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined CNS depression and altered perception. - Other NMDA antagonists: risk of excessive inhibition.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may exacerbate confusion. - CNS depressants (e.g., benzodiazepines): enhanced drowsiness. - Diuretics: potential impact on blood pressure and electrolyte balance.